Fresenius SE & Co. KGaA, a prominent player in the German healthcare sector, announced on Monday that its subsidiary, Fresenius Kabi, has completed the transfer of ownership for Laboratorio Sanderson S.A. in Chile to the Peruvian pharmaceutical company, Medifarma. The financial specifics of this transaction were not disclosed.
The divestiture encompasses the IV Laboratorio Sanderson facility located in Santiago de Chile. Fresenius Kabi confirmed that Medifarma will maintain the production of the current product portfolio in Chile.
This sale represents a strategic move for Fresenius Kabi aimed at reducing operational complexity and enhancing efficiency within its global manufacturing operations. Despite this divestiture, Fresenius Kabi will remain active in both the Chilean and South American markets.
This realignment is part of Fresenius' ongoing efforts to streamline the production network of Fresenius Kabi in accordance with its Vision 2026 and #FutureFresenius initiatives.
